Pharmacologic adjuvants to epoetin in the treatment of anemia in patients on hemodialysis

Hemodialysis International

Volumn 9, Issue 1, 2005, Pages 7-22

  Berns, Jeffrey S ^a   Mosenkis, Ari ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Androgens; Ascorbic acid; Carnitine; Functional iron deficiency; Vitamin C

Indexed keywords

ALPHA TOCOPHEROL; ANDROGEN; ASCORBIC ACID; CARNITINE; CYANOCOBALAMIN; FOLIC ACID; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; NANDROLONE DECANOATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PENTOXIFYLLINE; PLACEBO; PYRIDOXINE; RECOMBINANT ERYTHROPOIETIN;

ACNE; ADJUVANT THERAPY; ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; HEMATOMA; HEMODIALYSIS; HUMAN; INJECTION PAIN; OXALOSIS; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

ADJUVANTS, PHARMACEUTIC; ANDROGENS; ANEMIA, IRON-DEFICIENCY; ANTIOXIDANTS; ASCORBIC ACID; CARNITINE; ERYTHROPOIETIN; FEMALE; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; MALE; PRACTICE GUIDELINES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 21644451973     PISSN: 14927535     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1492-7535.2005.01113.x     Document Type: Review

References (91)

1. Eschbach JW, Adamson JW. Anemia of end-stage renal disease (ESRD). Kidney Int. 1985; 28(1):1-5.
2. Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol. 2000; 20(4):345-349.
3. Collins AJ, Li S, St Peter W, Ebben J, Roberts T, Ma JZ, Manning W. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36% to 39%. J Am Soc Nephrol. 2001; 12(11):2465-2473.
4. Teruel JL, Marcen R, Navarro-Antolin J, Aguilera A, Fernandez-Juarez G, Ortuno J. Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients: A prospective study. J Am Soc Nephrol. 1996; 7(1):140-144.
5. Gascon A, Belvis JJ, Berisa F, Iglesias E, Estopinan V, Teruel JL. Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis. Geriatr Nephrol Urol. 1999; 9(2):67-72.
6. Navarro JF, Mora-Fernandez C, Rivero A, Macia M, Gallego E, Chahin J, Mendez ML, Garcia J. Androgens for the treatment of anemia in peritoneal dialysis patients. Adv Perit Dial. 1998; 14:232-235.
7. Navarro JF, Mora C, Macia M, Garcia J. Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney Int. 2002; 61(4):1537-1544.
8. Ballal SH, Domoto DT, Polack DC, Marciulonis P, Martin KJ. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis. 1991; 17(1):29-33.
9. Berns JS, Rudnick MR, Cohen RM. A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. Clin Nephrol. 1992; 37(5):264-267.
10. Gaughan WJ, Liss KA, Dunn SR, Mangold AM, Buhsmer JP, Michael B, Burke JR. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. Am J Kidney Dis. 1997; 30(4):495-500.
11. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis. 2001; 37(1 Suppl 1):S182-S238.
12. Revised European best practices guidelines for the management of anaemia in patients with chronic renal failure: Section III. Treatment of renal anaemia. Nephrol Dial Transplant. 2004; 19:II16-II31.
13. Teruel JL, Aguilera A, Marcen R, Navarro Antolin J, Garcia Otero G, Ortuno J. Androgen therapy for anaemia of chronic renal failure: Indications in the erythropoietin era. Scand J Urol Nephrol. 1996; 30(5):403-408.
14. Powe NR, Griffiths RI, Bass EB. Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease. J Am Soc Nephrol. 1993; 3(10):1660-1671.
15. Bridges KR, Hoffman KE. The effects of ascorbic acid on the intracellular metabolism of iron and ferritin. J Biol Chem. 1986; 261(30):14273-14277.
16. Lipschitz DA, Bothwell TH, Seftel HC, Wapnick AA, Charlton RW. The role of ascorbic acid in the metabolism of storage iron. Br J Haematol. 1971; 20(2):155-163.
17. Goldberg A. The enzymic formation of haem by the incorporation of iron into protoporphyrin;importance of ascorbic acid, ergothioneine and glutathione. Br J Haematol. 1959; 5(2):150-157.
18. Sullivan JF, Eisenstein AB. Ascorbic acid depletion during hemodialysis. JAMA. 1972; 220(13):1697-1699.
19. Sullivan JF, Eisenstein AB, Mottola OM, Mittal AK. The effect of dialysis on plasma and tissue levels of vitamin C. Trans Am Soc Artif Intern Organs. 1972; 18(0):277-282.
20. Descombes E, Hanck AB, Fellay G. Water soluble vitamins in chronic hemodialysis patients and need for supplementation. Kidney Int. 1993; 43(6):1319-1328.
21. Wang S, Eide TC, Sogn EM, Berg KJ, Sund RB. Plasma ascorbic acid in patients undergoing chronic haemodialysis. Eur J Clin Pharmacol. 1999; 55(7): 527-532.
22. Gastaldello K, Vereerstraeten A, Nzame-Nze T, Vanherweghem JL, Tielemans C. Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Nephrol Dial Transplant. 1995; 10(Suppl 6):44-47.
23. Costello JF, Sadovnic MJ, Cottington EM. Plasma oxalate levels rise in hemodialysis patients despite increased oxalate removal. J Am Soc Nephrol. 1991; 1(12): 1289-1298.
24. Revised European best practices guidelines for the management of anaemia in patients with chronic renal failure: Section IV. Failure to respond to treatment Nephrol Dial Transplant 2004; 19:II32-II36.
25. Tarng DC, Huang TP. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. Nephrol Dial Transplant. 1998; 13(11):2867-2872.
26. Tarng DC, Wei YH, Huang TP, Kuo BI, Yang WC. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int. 1999; 55(6): 2477-2486.
27. Giancaspro V, Nuzziello M, Pallotta G, Sacchetti A, Petrarulo F. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: A clinical trial. J Nephrol. 2000; 13(6):444-449.
28. Sezer S, Ozdemir FN, Yakupoglu U, Arat Z, Turan M, Haberal M. Intravenous ascorbic acid administration for erythropoietin-hyporesponsive anemia in iron loaded hemodialysis patients. Artif Organs. 2002; 26(4): 366-370.
29. Lin CL, Hsu PY, Yang HY, Huang CC. Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload. Ren Fail. 2003; 25(3): 445-453.
30. Deira J, Diego J, Martinez R, Oyarbide A, Gonzalez A, Diaz H, Grande J. Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia. J Nephrol. 2003; 16(5):703-709.
31. Keven K, Kutlay S, Nergizoglu G, Erturk S. Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. Am J Kidney Dis. 2003; 41(6):1233-1239.
32. Tovbin D, Markowitz A, Mostoslavsky M, Landver R. Effectiveness of erythropoiesis on supervised intradialytic oral iron and vitamin C therapy is correlated with Kt/V and patient weight. Clin Nephrol. 2000; 53(4):276-282.
33. Balcke P, Schmidt P, Zazgornik J, Kopsa H, Haubenstock A. Ascorbic acid aggravates secondary hyperoxalemia in patients on chronic hemodialysis. Ann Intern Med. 1984; 101(3):344-345.
34. Pru C, Eaton J, Kjellstrand C. Vitamin C intoxication and hyperoxalemia in chronic hemodialysis patients. Nephron. 1985; 39(2):112-116.
35. Rolton HA, McConnell KM, Modi KS, Macdougall AI. The effect of vitamin C intake on plasma oxalate in patients on regular haemodialysis. Nephrol Dial Transplant. 1991; 6(6):440-443.
36. Eiselt J, Racek J, Trefil L, Opatrny K Jr. Effects of a vitamin E-modified dialysis membrane and vitamin C infusion on oxidative stress in hemodialysis patients. Artif Organs. 2001; 25(6):430-436.
37. Chen WT, Lin YF, Yu FC, Kao WY, Huang WH, Yan HC. Effect of ascorbic acid administration in hemodialysis patients on in vitro oxidative stress parameters: Influence of serum ferritin levels. Am J Kidney Dis. 2003; 42(1):158-166.
38. Berger TM, Polidori MC, Dabbagh A, Evans PJ, Halliwell B, Morrow JD, Roberts LJ 2nd, Frei B. Antioxidant activity of vitamin C in iron-overloaded human plasma. J Biol Chem. 1997; 272(25):15656-15660.
39. Hoppel C. The role of carnitine in normal and altered fatty acid metabolism. Am J Kidney Dis. 2003; 41(4 Suppl 4):S4-S12.
40. Bohmer T, Bergrem H, Eiklid K. Carnitine deficiency induced during intermittent haemodialysis for renal failure. Lancet. 1978; 1(8056):126-128.
41. Golper TA, Wolfson M, Ahmad S, Hirschberg R, Kurtin P, Katz LA, Nicora R, Ashbrook D, Kopple JD. Multicenter trial of l-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects. Kidney Int. 1990; 38(5):904-911.
42. Golper TA, Ahmad S. L-Carnitine administration to hemodialysis patients: Has its time come? Semin Dial. 1992; 5:94-98.
43. Ahmad S. L-Carnitine in dialysis patients. Semin Dial. 2001; 14:209-217.
44. Evans A. Dialysis-related carnitine disorder and levocarnitine pharmacology. Am J Kidney Dis. 2003; 41(4 Suppl 4):S13-S26.
45. Labonia WD, Morelli OH Jr, Gimenez MI, Freuler PV, Morelli OH. Effects of L-carnitine on sodium transport in erythrocytes from dialyzed uremic patients. Kidney Int. 1987; 32(5):754-759.
46. Matsumura M, Hatakeyama S, Koni I, Mabuchi H, Muramoto H. Correlation between serum carnitine levels and erythrocyte osmotic fragility in hemodialysis patients. Nephron. 1996; 72(4):574-578.
47. Nikolaos S, George A, Telemachos T, Maria S, Yannis M, Konstantinos M. Effect of L-carnitine supplementation on red blood cells deformability in hemodialysis patients. Ren Fail. 2000; 22(1): 73-80.
48. Labonia WD. L-Carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Am J Kidney Dis. 1995; 26(5):757-764.
49. Kletzmayr J, Mayer G, Legenstein E, Heinz-Peer G, Leitha T, Horl WH, Kovarik J. Anemia and carnitine supplementation in hemodialyzed patients. Kidney Int Suppl. 1999; 69:S93-S106.
50. Albertazzi A, Capelli P, Di Paolo B, Pola P, Tondi P, Vaccario O. Endocrine-metabolic effects of l-carnitine in patients on regular dialysis treatment. Proc Eur Dial Transplant Assoc. 1983; 19:302-307.
51. Trovato GM, Ginardi V, DiMarco V, Dell'Aira AE, Corsi M. Long-term l-carnitine treatment of chronic anaemia of patients with end-stage renal failure. Clin Ther Res. 1982; 31:1042-1049.
52. Bellinghieri G, Savica V, Mallamace A, Di Stefano C, Consolo F, Spagnoli LG, Villaschi S, Palmieri G, Corsi M, Maccari F. Correlation between increased serum and tissue L-carnitine levels and improved muscle symptoms in hemodialyzed patients. Am J Clin Nutr. 1983; 38(4):523-531.
53. Donatelli M, Terrizzi C, Zumro G, Russo V, Bucalo M, Scarpinaro A. Effects of L-carnitine on chronic anemia and adenosine triphosphate concentration in hemodialyzed patients. Curr Ther Res. 1987; 41:621-624.
54. Vacha GM, Giorcelli G, Siliprandi N, Corsi M. Favorable effects of L-carnitine treatment on hypertriglyceridemia in hemodialysis patients: Decisive role of low levels of high-density lipoprotein-cholesterol. Am J Clin Nutr. 1983; 38(4):532-540.
55. Nilsson-Ehle P, Cederblad G, Fagher B, Monti M, Thysell H. Plasma lipoproteins, liver function and glucose metabolism in haemodialysis patients. Lack of effect of L-carnitine supplementation. Scand J Clin Lab Invest. 1985; 45(2):179-184.
56. Kooistra MP, Struyvenberg A, van Es A. The response to recombinant human erythropoietin in patients with the anemia of end-stage renal disease is correlated with serum carnitine levels. Nephron. 1991; 57(1):127-128.
57. Berard E, Iordache A. Effect of low doses of L-carnitine on the response to recombinant human erythropoietin in hemodialyzed children: about two cases. Nephron. 1992; 62(3):368-369.
58. Boran M, Dalva I, Gonenc F, Cetin S. Response to recombinant human erythropoietin (r-Hu EPC) and L-carnitine combination in patients with anemia of end-stage renal disease. Nephron. 1996; 73(2): 314-315.
59. Kavadias D, Fourtounas C, Tsouchnikas J, Barboutis K. L-Carnitine and erythropoietin requirements in hemodialysis patients. Am J Kidney Dis. 1996; 28(1):156.
60. Trovato GM, Iannetti E, Murgo AM, Carpinteri G, Catalano D. Body composition and long-term levo-carnitine supplementation. Clin Ter. 1998; 149(3): 209-214.
61. Caruso U, Leone L, Cravotto E, Nava D. Effects of L-carnitine on anemia in aged hemodialysis patients treated with recombinant human erythropoietin: A pilot study. Dial Transplant. 1998; 27:498-506.
62. Matsumoto Y, Amano I, Hirose S, Tsuruta Y, Hara S, Murata M, Imai T. Effects of L-carnitine supplementation on renal anemia in poor responders to erythropoietin. Blood Purif. 2001; 19(1):24-32.
63. Vesela E, Racek J, Trefil L, Jankovy'ch V, Pojer M. Effect of L-carnitine supplementation in hemodialysis patients. Nephron. 2001; 88(3):218-223.
64. Vaux EC, Taylor DJ, Altmann P, Rajagopalan B, Graham K, Cooper R, Bonomo Y, Styles P. Effects of carnitine supplementation on muscle metabolism by the use of magnetic resonance spectroscopy and near-infrared spectroscopy in end-stage renal disease. Nephron Clin Pract. 2004; 97(2):c41-c48.
65. Hurot JM, Cucherat M, Haugh M, Fouque D. Effects of L-carnitine supplementation in maintenance hemodialysis patients: A systematic review. J Am Soc Nephrol. 2002; 13(3):708-714.
66. Keith RE. Symptoms of carnitine-like deficiency in a trained runner taking DL-carnitine supplements. JAMA. 1986; 255:1137.
67. McCarty MF. A note on "orthomolecular aids for dieting" - myasthenic syndrome due to DL-carnitine. Med Hypotheses. 1982; 9(6):661-662.
68. Consensus Group statement: Role of L-carnitine in treating renal dialysis patients. Dial Transplant. 1994; 23:177-181.
69. Eknoyan G, Latos DL, Lindberg J. National Kidney Foundation Carnitine Consensus Converence. Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. Am J Kidney Dis. 2003; 41(4):868-876.
70. Steinman TI, Nissenson AR, Glassock RJ, Dickmeyer J, Mattern WD, Parker TF 3rd, Hull AR. L-Carnitine use in dialysis patients: Is national coverage for supplementation justified? What were CMS regulators thinking - or were they? Nephrol News Issues. 2003; 17(5):28-30, 32-24, 36 passim.
71. Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation. Am J Kidney Dis. 2000; 35(6 Suppl 2):S1-S140.
72. Benbernou N, Esnault S, Potron G, Guenounou M. Regulatory effects of pentoxifylline on T-helper cell-derived cytokine production in human blood cells. J Cardiovasc Pharmacol. 1995; 25(Suppl 2):S75-S79.
73. Bienvenu J, Doche C, Gutowski MC, Lenoble M, Lepape A, Perdrix JP. Production of proinflammatory cytokines and cytokines involved in the TH1/TH2 balance is modulated by pentoxifylline. J Cardiovasc Pharmacol. 1995; 25(Suppl 2):S80-S84.
74. Navarro JF, Mora C, Garcia J, Rivero A, Macia M, Gallego E, Mendez ML, Chahin J. Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure. Scand J Urol Nephrol. 1999; 33(2):121-125.
75. Cooper A, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol. 2004; 15(7): 1877-1882.
76. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001; 21(11):1712-1719.
77. Shishehbor MH, Brennan ML, Aviles RJ, Aviles RJ, Fu X, Penn MS, Sprecher DL, Hazen SL. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. 2003; 108(4):426-431.
78. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr; Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001; 344(26): 1959-1965.
79. Sirken G, Kung SC, Raja R. Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy. ASAIO J. 2003; 49(4):422-425.
80. Hutchinson FN, Jones WJ. A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease. Am J Kidney Dis. 1997; 29(5):651-657.
81. Pronai W, Riegler-Keil M, Silberbauer K, Stockenhuber F. Folic acid supplementation improves erythropoietin response. Nephron. 1995; 71(4):395-400.
82. Ono K, Hisasue Y. Is folate supplementation necessary in hemodialysis patients on erythropoietin therapy. Clin Nephrol. 1992; 38(5):290-292.
83. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, Selhub J, Rosenberg IH. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int. 1996; 49(1):147-152.
84. Cristol JP, Bosc JY, Badiou S, Leblanc M, Lorrho R, Descomps B, Canud B. Erythropoietin and oxidative stress in haemodialysis: Beneficial effects of vitamin E supplementation. Nephrol Dial Transplant. 1997; 12(11):2312-2317.
85. Nemeth I, Turi S, Haszon I, Bereczki C. Vitamin E alleviates the oxidative stress of erythropoietin in uremic children on hemodialysis. Pediatr Nephrol. 2000; 14(1):13-17.
86. Ono K. Effects of large dose vitamin E supplementation on anemia in hemodialysis patients. Nephron. 1985; 40(4):440-445.
87. Sinsakul V, Drake JR, Leavitt JN Jr, Harrison BR, Fitch CD. Lack of effect of vitamin E therapy on the anemia of patients receiving hemodialysis. Am J Clin Nutr. 1984; 39(2):223-226.
88. Nakatan T, Takemoto Y, Tsuchida AK. The effect of vitamin E-bonded dialyzer membrane on red blood cell survival in hemodialyzed patients. Artif Organs. 2003; 27(3):214-217.
89. Usberti M, Gerardi G, Bufano G, Tira P, Micheli A, Albertini A, Floridi A, Di Lornezo D, Galli F. Effects of erythropoietin and vitamin E-modified membrane on plasma oxidative stress markers and anemia of hemodialyzed patients. Am J Kidney Dis. 2002; 40(3):590-599.
90. Usberti M, Gerardi G, Micheli A, Tira P, Bufano G, Gaggia P, Movilli E, Cancarini GC, De Marinis S, D'Avolio G, Broccoli R, Manganoni A, Albertin A, Di Lorenzo D. Effects of a vitamin E-bonded membrane and of glutathione on anemia and erythropoietin requirements in hemodialysis patients. J Nephrol. 2002; 15(5):558-564.
91. Triolo L, Malaguti M, Ansali F, Comunian MC, Arcangeloni O, Coppolin F, Marrocco F, Sicoli R, Biagini M. Vitamin E-bonded cellulose membrane, lipoperoxidation, and anemia in hemodialysis patients. Artif Cells Blood Substit Immobil Biotechnol. 2003; 31(2):185-191.